Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Phase of Trial: Phase II/III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Cycloserine/lurasidone (Primary) ; Lurasidone
- Indications Bipolar depression
- Focus Biomarker; Therapeutic Use
- Acronyms NRX-GLX
- Sponsors NeuroRX
- 29 Nov 2018 Planned End Date changed from 31 Mar 2019 to 28 Feb 2020.
- 29 Nov 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Dec 2019.
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.